Maximizing process control and efficiency in CAR-T cell manufacturing

The complexity of CAR-T cell manufacturing poses a barrier to the wider accessibility and uptake of transformative CAR-T cell-based therapies. The ability to complete T cell isolation and activation in a single, automated step can enable a simpler workflow, resulting in time savings and process control improvements. In addition, the development of non-viral and scalable CAR-T workflows can support increased genome editing efficiency, enhanced precision, and higher expansion of CAR-T cells. Here, we introduce available off-the-shelf technology to enable one-step isolation and activation, and present data demonstrating the ability to integrate several CAR-T process steps combining multiple platforms in a closed, automated workflow. A non-viral system for the expansion of CAR-T cells is explored alongside a scalable platform to improve the growth of desirable T cell phenotypes.

Please enter your email to access content Read now